[Clinical response to agonists of mu and beta opiate receptors in patients with ischemic heart disease: effects of D-Ala2-Leu5-Arg6-enkephalin on hemodynamics, oxygen balance and lipid spectrum of blood].
Effects of intravenous dalargin daily administered in a dose of 28 micrograms/kg during 7 days on hemodynamics, oxygen balance, lipid spectrum were studied in patients with coronary heart disease. The results of the treatment show that dalargin decreases incidence of anginal attacks, peripheral vascular resistance, venous tonicity, increases exercise tolerance, peripheral blood flow and venous flow. In addition, such treatment reduces oxygen consumption, levels of total cholesterol, triglycerides, low density lipoprotein cholesterol.
D000318:Adrenergic beta-Agonists / Q000378:metabolism*; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D016308:Enkephalin, Leucine-2-Alanine / Q000031:analogs & derivatives* / Q000494:pharmacology* / Q000627:therapeutic use*; D004745:Enkephalins / Q000494:pharmacology* / Q000627:therapeutic use*; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007275:Injections, Intravenous; D008074:Lipoproteins / Q000097:blood* / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000188:drug therapy*; D011957:Receptors, Opioid / Q000378:metabolism*; D017450:Receptors, Opioid, mu / Q000378:metabolism*
D000318:Adrenergic beta-Agonists; D000889:Anti-Arrhythmia Agents; D004745:Enkephalins; D008074:Lipoproteins; D011957:Receptors, Opioid; D017450:Receptors, Opioid, mu; D016308:Enkephalin, Leucine-2-Alanine; C040996:enkephalin-Leu, Ala(2)-Arg(6)-
Klinicheskaia éffektivnost' agonista gamma- i beta-opiatnykh retseptorov u bol'nykh ishemicheskoĭ bolezn'iu serdtsa: vliianie D-Ala2-Leu5-Arg6-énkefalina na pokazateli gemodinamiki, kislorodnyĭ balans i lipidnyĭ spektr krovi.